Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison

Phase 3CompletedNCT00767975

National Taiwan University Hospital2,384 enrolled

Overview

LTBI Treatment is effective in prison

LTBI treatment will be conducted in a prison with either isoniazid or rifampin

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

2,384

Conditions

Tuberculosis

Interventions

isoniazid , randomized, open labelDRUG

isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)

rifampin, randomized, open labelDRUG

rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * all people who is LTBI, and have ability to sign the informed concent Exclusion Criteria: * previously adverse effect from anti-TB medication complete treatment of TB in the pass; active TB AST, ALT \> 3 times of normal limit platelet \< 150 k/mm3 T-bil \> 2 times of normal limit

Locations (1)

Taipei Prison

Taoyuan, Taiwan

Outcomes

Primary Outcomes

COMPLETE RATE OF LTBI TREATMENT

Time frame: 1.5 year

Secondary Outcomes

Efficacy

Time frame: 3 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.